New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
09:58 EDTSTO, WEX, SNE, NFLX, LULU, EDMC, ANR, LNKD, LLL, HHS, TW, SGNT, MYGN, LII, CMI, OAS, SYT, XPO, SBUX, NBL, MMP, K, CHRW, CSLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alpha Natural (ANR) upgraded to Neutral from Sell at Citigroup... C.H. Robinson (CHRW) upgraded to Hold from Sell at Stifel... Cummins (CMI) upgraded to Outperform from Market Perform at Wells Fargo... Education Management (EDMC) upgraded to Market Perform at BMO Capital... Kellogg (K) upgraded to Neutral from Underweight at JPMorgan... Lennox (LII) upgraded to Equal Weight from Underweight at Morgan Stanley... lululemon (LULU) upgraded to Outperform from Sector Perform at RBC Capital... Magellan Midstream (MMP) upgraded to Outperform from Market Perform at Wells Fargo... Myriad Genetics (MYGN) upgraded to Neutral from Underperform at Credit Suisse... Netflix (NFLX) upgraded to Buy from Hold at Stifel... Noble Energy (NBL) upgraded to Buy from Neutral at Mizuho... Sagent Pharmaceuticals (SGNT) upgraded to Buy from Neutral at BofA/Merrill... Sony (SNE) upgraded to Buy from Hold at Jefferies... Starbucks (SBUX) upgraded to Outperform from Market Perform at Wells Fargo... Towers Watson (TW) upgraded to Overweight from Neutral at JPMorgan... WEX Inc. (WEX) upgraded to Neutral from Underweight at JPMorgan... XPO Logistics (XPO) upgraded to Buy from Hold at Stifel... Harte-Hanks (HHS) upgraded to Buy from Hold at Noble Financial... Statoil (STO) upgraded to Focus List from Outperform at Howard Weil... Syngenta (SYT) upgraded to Market Perform from Underperform at Bernstein... L-3 Communications (LLL) upgraded at Cowen... Carlisle (CSL) upgraded to Outperform from Market Perform at BMO Capital... Oasis Petroleum (OAS) upgraded to Buy from Hold at Canaccord... LinkedIn (LNKD) upgraded to Buy from Neutral at SunTrust.
News For ANR;CHRW;CMI;EDMC;K;LII;LULU;MMP;MYGN;NFLX;NBL;SGNT;SNE;SBUX;TW;WEX;XPO;HHS;STO;SYT;LLL;CSL;OAS;LNKD From The Last 14 Days
Check below for free stories on ANR;CHRW;CMI;EDMC;K;LII;LULU;MMP;MYGN;NFLX;NBL;SGNT;SNE;SBUX;TW;WEX;XPO;HHS;STO;SYT;LLL;CSL;OAS;LNKD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 3, 2014
15:39 EDTKKellogg calls active on sharp rally
Subscribe for More Information
15:34 EDTKKellogg near highs, up 5% to $65.77
Subscribe for More Information
12:32 EDTNFLXNetflix heads for support test at $350 area
Subscribe for More Information
10:49 EDTLULULululemon Athletica active call volume attributed to renewed takeover chatter
Lululemon Athletica active April weekly 55 and 56 call total call volume is attributed to renewed takeover chatter. April weekly call option implied volatility is at 43, April is at 34, June is at 38; compared to its 26-week average of 37 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
10:34 EDTLULURumor: lululemon strength attributed to unconfirmed takeover speculation
09:37 EDTLNKDActive equity options trading on open
Subscribe for More Information
09:07 EDTMMPMagellan Midstream's pipeline project in Little Rock advances to next phase
Magellan Midstream received sufficient commitments through its recent open season to proceed to the next phase for its potential pipeline to Little Rock, Arkansas. Management is currently negotiating an agreement to utilize a portion of an existing third-party pipeline. Subject to finalizing this agreement and receipt of the necessary permits and regulatory approval for the pipeline construction, the potential Little Rock pipeline could be operational in late 2015.
07:37 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho raised Myriad's price target to $40 from $28 following the better than expected CMS pricing for BRCA testing. Shares are Neutral rated.
April 2, 2014
16:21 EDTMYGN, NFLXOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTNFLXOptions Update; April 2, 2014
Subscribe for More Information
13:46 EDTNFLXNetflix heads lower, levels to watch
The shares have been steadily declining for the last hour, last at $359.97. At that price next immediate support is at the session low of $358.46. A more important test is at $352.06. A break below $350 would breach an important technical level which had been resistance prior to the run up to the life high early last month. Resistance is at $364.69, the prior session close.
12:20 EDTANRCoal stocks higher after BHP executive signals confidence
Subscribe for More Information
11:22 EDTNFLXAmazon says Fire TV remote control uses bluetooth
Subscribe for More Information
11:08 EDTLULUOptions with decreasing implied volatility: LULU VJET APOL RHT GME
Subscribe for More Information
10:35 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho said the final CMS pricing for Myriad's BRCA testing represents a cut of about 20%, but that is still less severe than originally outlined. The firm raised its price target on Myriad Genetics to $40 following the ruling, but maintains its Neutral rating on the stock.
09:55 EDTNFLXReport: Netflix to launch in France from Luxembourg, Variety says
Subscribe for More Information
09:18 EDTMYGNOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTMYGNLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.
07:19 EDTMYGNMyriad Genetics price target raised to $44 from $42 at Cantor
Cantor increased its price target on Myriad Genetics after CMS raised prices for the company's BRCA 1&2 tests by about 52%, according to the firm. Cantor raised its estimates for Myriad Genetics and keeps a Buy rating on the stock.
06:18 EDTNFLXHulu, Comcast expected to strike deal for past NBCU shows, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use